Fenebrutinib — Investigational Agent
BTK Inhibitor · Phase 2 · Genentech / Roche
Mechanism of Action
Non-covalent (reversible), highly selective BTK inhibitor developed via structure-based drug design. Fenebrutinib's key distinction is exceptional kinase selectivity — it has minimal activity against ITK (interleukin-2-inducible T-cell kinase) and other TEC-family kinases, unlike ibrutinib which potently inhibits ITK. ITK is required for NK cell and CD8+ T-cell cytotoxicity; its preservation by fenebrutinib may maintain superior immune surveillance compared to ibrutinib. Also active against the C481S BTK resistance mutation.
Investigational Indications
- Relapsed/refractory non-Hodgkin lymphoma (NHL)
- Relapsed/refractory CLL/SLL
- Rheumatoid arthritis (separate non-oncology program)